The platform of Refuge is a synthetic biology system leveraging an expression modulation strategy to repress or activate transcription of target genes. Early pre-clinical data indicate a potential
Under the deal terms, Jazz will get exclusive rights to develop and market the antibody across all indications in the US, Japan, Europe, as well as all other
The collaboration will use Charles River’s contract development and manufacturing (CDMO) services to manufacture plasmid DNA and viral vectors for late-stage clinical trials that target degenerative ocular diseases,
The approval was granted based on data obtained from the pivotal Phase III ZUMA-7 study, which is said to be the largest and longest trial of a Chimeric
Under the terms of the deal, the company will be responsible for the supply of 100,000 doses of the vaccine. The company will seek regulatory approval of the
The regulator has recommended the radioligand therapy along with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition to treat progressive PSMA- positive mCRPC adult
The companies will assess AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR’s combination inhibition technique. AdAlta owns an i-bodies panel that inhibit CXCR4 signalling in different ways.
The company is seeking regulatory approval for SIS-101-ADO to treat Autosomal Dominant Osteopetrosis Type 2 (ADO2) patients. CSSi LifeSciences will be responsible for coordinating the regulatory process that
The CRISPR-based gene therapy has been indicated to treat Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS). It has been designed to target Shiga toxins from
The injection (abbreviated as relma-cel ) has been approved to treat adult patients with follicular lymphoma that relapses or is refractory in 24 months of second-line or above
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.